You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

Sanofi Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Sanofi

Drugs and US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us LORELCO probucol TABLET;ORAL 017535-002 Jul 6, 1988 DISCN No No ⤷  Try for Free ⤷  Try for Free
Sanofi Aventis Us METATENSIN #4 reserpine; trichlormethiazide TABLET;ORAL 012972-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-003 May 1, 1984 AB2 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Sanofi Aventis Us PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER milrinone lactate INJECTABLE;INJECTION 020343-001 Aug 9, 1994 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us ARAVA leflunomide TABLET;ORAL 020905-002 Sep 10, 1998 4,351,841 ⤷  Try for Free
Sanofi Aventis Us AUBAGIO teriflunomide TABLET;ORAL 202992-002 Sep 12, 2012 5,679,709 ⤷  Try for Free
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-002 May 1, 1984 3,454,635 ⤷  Try for Free
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007 6,509,013 ⤷  Try for Free
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-003 May 1, 1984 3,426,067 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SANOFI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 2007-07-16
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe 2006-12-07
➤ Subscribe Tablets 150 mg/12.5 mg and 300 mg/12.5 mg ➤ Subscribe 2004-11-10
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe 2004-05-25
➤ Subscribe Capsules 0.5 mcg and 2.5 mcg ➤ Subscribe 2009-03-25
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-03-04
➤ Subscribe Capsules 1 mcg ➤ Subscribe 2010-02-12
➤ Subscribe Tablets 800 mg ➤ Subscribe 2008-12-04
➤ Subscribe Injection 40 mg/mL, 0.5 mL and 2 mL vials ➤ Subscribe 2009-06-30
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2007-02-09
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 2011-03-23
➤ Subscribe Tablets 7 mg and 14 mg ➤ Subscribe 2016-09-12
➤ Subscribe Tablets 300 mg/25 mg ➤ Subscribe 2006-06-06
➤ Subscribe Capsules 0.4 mg ➤ Subscribe 2004-12-20
➤ Subscribe Tablets 400 mg ➤ Subscribe 2013-07-01
➤ Subscribe Injection 2 mcg/mL, 2 mL ampules ➤ Subscribe 2007-10-15
➤ Subscribe Injection 2 mcg/mL, 1 mL in 2 mL vial ➤ Subscribe 2011-12-28
➤ Subscribe Powder for Oral Suspension 0.8 g/packet and 2.4 g/packet ➤ Subscribe 2009-12-30
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2007-02-09

Supplementary Protection Certificates for Sanofi Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1381356 C01381356/01 Switzerland ⤷  Try for Free FORMER OWNER: AVENTISUB LLC, US
1381356 92366 Luxembourg ⤷  Try for Free PRODUCT NAME: TERIFLUNOMIDE,SON STEREOISOMERE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES
1381356 8/2014 Austria ⤷  Try for Free PRODUCT NAME: TERIFLUNOMID, SEINE STEREOISOMERE AND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/13/838 20130826
0281459 35/1998 Austria ⤷  Try for Free PRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
1667986 C01667986/01 Switzerland ⤷  Try for Free PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: SWISSMEDIC 61543 06.04.2011
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Sanofi – Market Position, Strengths & Strategic Insights

Last updated: February 12, 2025

In the ever-evolving pharmaceutical industry, Sanofi has emerged as a formidable player, consistently demonstrating its ability to adapt and thrive in a competitive landscape. As we delve into Sanofi's market position, strengths, and strategic insights, we'll uncover the factors that have propelled this pharmaceutical giant to the forefront of the industry.

Sanofi's Market Position

Sanofi has solidified its position as one of the top pharmaceutical companies globally. As of 2024, Sanofi ranks as the eighth largest pharmaceutical company in the world by revenue[2]. This impressive standing is a testament to the company's robust product portfolio and strategic growth initiatives.

Global Presence and Market Share

With operations spanning over 170 countries, Sanofi boasts a truly global footprint[8]. This extensive reach allows the company to tap into diverse markets and maintain a strong presence across various regions. In 2022, Sanofi held approximately 3.8% of the global pharmaceutical market share[5], demonstrating its significant influence in the industry.

Key Markets and Revenue Distribution

Sanofi's revenue distribution highlights its strategic focus on key markets:

  • United States: 35% of revenue
  • Europe: 25% of revenue
  • Emerging Markets: 20% of revenue[5]

This balanced approach allows Sanofi to capitalize on established markets while also tapping into the growth potential of emerging economies.

Sanofi's Strengths and Competitive Advantages

Sanofi's success can be attributed to several key strengths that set it apart from its competitors.

Diverse Product Portfolio

One of Sanofi's primary strengths lies in its diverse portfolio of pharmaceuticals, vaccines, and consumer healthcare products[3]. This broad range of offerings allows the company to:

  1. Cater to a wide spectrum of patient needs
  2. Address multiple therapeutic areas
  3. Adapt to changing market dynamics
  4. Mitigate risks associated with dependence on a single product or therapeutic area

Focus on Research and Development

Sanofi demonstrates a strong commitment to research and development (R&D), consistently investing in innovation and advancement in healthcare solutions. In 2020, Sanofi invested over €5.9 billion in R&D[3], showcasing its dedication to staying at the forefront of medical advancements.

"2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth" - Paul Hudson, CEO of Sanofi[2]

This focus on R&D has enabled Sanofi to:

  • Develop new treatments and therapies
  • Address various health conditions
  • Improve patient outcomes
  • Maintain a competitive edge in the industry

Strong Market Presence in Key Therapeutic Areas

Sanofi has established a strong presence in several key therapeutic areas, including:

  1. Diabetes care: 7.2% market share
  2. Vaccine market: 6.5% market share[5]

These significant market shares in crucial areas contribute to Sanofi's overall competitive position and revenue growth.

Strategic Initiatives and Future Outlook

Sanofi has implemented several strategic initiatives to drive growth and maintain its competitive edge in the pharmaceutical industry.

Play to Win Strategy

In October 2023, Sanofi provided a comprehensive update on its Play to Win strategy, which focuses on:

  1. Executing transformative medicine and vaccine launches
  2. Driving agile and efficient resource deployment
  3. Enhancing R&D productivity[4]

As part of this strategy, Sanofi announced plans to increase its R&D investments to fully realize its pipeline potential and drive long-term growth.

Consumer Healthcare Business Separation

Sanofi has announced its intention to separate its Consumer Healthcare Business, enabling greater management focus and resource allocation to the Biopharma business[4]. This strategic move is expected to create value-creating opportunities and longer-term operational levers to support accelerated R&D investments.

Focus on Immunology and Neuro-inflammation

Sanofi is developing an industry-leading immunology and strong neuro-inflammation pipeline, with currently 7 assets in mid- to late-stage development. Each of these assets has a peak sales potential of at least €2 to €5 billion[4], highlighting the company's commitment to addressing unmet medical needs in these areas.

Cost Savings and Reinvestment

To support its growth initiatives, Sanofi is executing a €2.7 billion cost savings plan. These savings will be reinvested in the company's growth drivers[4], ensuring a sustainable approach to long-term success.

Strategic Partnerships and Acquisitions

Sanofi has been actively pursuing strategic partnerships and acquisitions to strengthen its pipeline and enhance its technological capabilities. Some notable examples include:

  1. A $140 million partnership with French tech company Aqemia to revolutionize drug discovery using physics algorithms and generative artificial intelligence[2].
  2. Investing in over 25 value-creating business development and M&A deals to further strengthen Sanofi's pipeline[4].

Competitive Landscape and Industry Trends

To fully appreciate Sanofi's market position, it's essential to understand the competitive landscape and industry trends shaping the pharmaceutical sector.

Key Competitors

Sanofi operates in a highly competitive market, with several major players vying for market share. Some of Sanofi's key competitors include:

Competitor Global Pharmaceutical Revenue 2022 Key Therapeutic Areas
Pfizer $100.3 billion Vaccines, Oncology, Rare Diseases
GlaxoSmithKline $44.2 billion Vaccines, Respiratory, HIV
Merck & Co $57.9 billion Oncology, Vaccines, Diabetes
Sanofi $44.1 billion Diabetes, Oncology, Rare Diseases

[5]

This competitive landscape drives innovation and encourages the development of new therapies, ultimately benefiting patients by providing a variety of treatment options.

Industry Trends Shaping the Future

Several key trends are shaping the future of the pharmaceutical industry, and Sanofi is positioning itself to capitalize on these opportunities:

  1. AI-driven drug discovery
  2. Clinical trials technology
  3. Digital pharmacy tech
  4. Digital therapeutics[9]

Sanofi is actively investing in and partnering with companies in these areas to stay ahead of the curve and drive innovation in drug development and patient care.

SWOT Analysis: Sanofi's Strengths, Weaknesses, Opportunities, and Threats

A comprehensive SWOT analysis provides valuable insights into Sanofi's current position and future prospects.

Strengths

  1. Global presence in over 170 countries
  2. Diverse product portfolio spanning multiple therapeutic areas
  3. Strong focus on R&D and innovation
  4. Established market leadership in key areas like diabetes care and vaccines
  5. Robust pipeline of potential new molecular entities

Weaknesses

  1. Dependence on key products like Dupixent for growth
  2. Challenges in some legacy product lines
  3. Exposure to patent expirations and generic competition

Opportunities

  1. Expanding presence in emerging markets
  2. Leveraging AI and technology for drug discovery and development
  3. Growing demand for innovative treatments in areas like immunology and oncology
  4. Potential for strategic acquisitions and partnerships

Threats

  1. Intense competition from other pharmaceutical giants
  2. Regulatory challenges and pricing pressures
  3. Potential disruptions in global supply chains
  4. Rapid technological advancements requiring continuous adaptation

Future Prospects and Growth Strategy

Looking ahead, Sanofi's future prospects appear promising, driven by its strategic initiatives and focus on key growth areas.

Accelerating R&D Investments

Sanofi's commitment to increasing R&D investments is expected to fuel long-term growth and enhance shareholder value. By focusing on high-value innovation, the company aims to deliver breakthrough science that improves people's lives[4].

Expanding in Key Therapeutic Areas

Sanofi's strong pipeline in immunology and neuro-inflammation, with 7 assets in mid- to late-stage development, positions the company for significant growth in these areas[4]. Each of these assets has the potential to generate substantial revenue, contributing to Sanofi's future success.

Leveraging Technology and AI

By embracing AI-driven drug discovery and other technological advancements, Sanofi is positioning itself as a development-driven, tech-powered biopharma company[2]. This focus on innovation is expected to accelerate growth and improve the efficiency of drug development processes.

Strategic Partnerships and Acquisitions

Sanofi's continued investment in value-creating business development and M&A deals is likely to strengthen its pipeline and expand its capabilities in key areas[4]. These strategic moves will help the company stay competitive and drive future growth.

Key Takeaways

  1. Sanofi ranks as the eighth largest pharmaceutical company globally, with a strong presence in over 170 countries.
  2. The company's diverse product portfolio and focus on R&D are key strengths driving its competitive advantage.
  3. Sanofi's Play to Win strategy emphasizes increased R&D investments and focus on key therapeutic areas like immunology and neuro-inflammation.
  4. The separation of the Consumer Healthcare Business is expected to create value and support accelerated R&D investments.
  5. Sanofi is actively pursuing strategic partnerships and acquisitions to enhance its technological capabilities and strengthen its pipeline.
  6. The company is well-positioned to capitalize on industry trends such as AI-driven drug discovery and digital therapeutics.
  7. Future growth prospects are promising, driven by a strong pipeline and focus on high-value innovation.

FAQs

  1. Q: What is Sanofi's global market share in the pharmaceutical industry? A: As of 2022, Sanofi held approximately 3.8% of the global pharmaceutical market share.

  2. Q: How much does Sanofi invest in Research and Development? A: In 2020, Sanofi invested over €5.9 billion in R&D, demonstrating its strong commitment to innovation.

  3. Q: What are Sanofi's key therapeutic areas? A: Sanofi focuses on several key therapeutic areas, including diabetes, oncology, immunology, and rare diseases.

  4. Q: How is Sanofi leveraging artificial intelligence in its operations? A: Sanofi is partnering with companies to speed up drug discovery using AI and has formed a $140 million partnership with Aqemia to revolutionize drug discovery using physics algorithms and generative AI.

  5. Q: What is Sanofi's Play to Win strategy? A: The Play to Win strategy focuses on executing transformative medicine and vaccine launches, driving agile resource deployment, and enhancing R&D productivity to drive long-term growth and innovation.

Sources cited: [1] https://www.sanofi.com/en/media-room/press-releases/2024/2024-07-25-05-30-00-2918503 [2] https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2024 [3] https://blog.osum.com/sanofi-swot-analysis/ [4] https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-27-05-30-00-2768148 [5] https://dcfmodeling.com/products/sny-porters-five-forces-analysis [8] https://pitchgrade.com/companies/sanofi [9] https://www.cbinsights.com/research/sanofi-strategy-map-investments-partnerships/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.